Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Original statement
لكن التكميم ده بيموت منه بقى اصلا فانت خليت السرطان ده لما يجي عند سن 550 سنه جه عند سن 55 سنه
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live!التكميم (Open source)
- Published
- 6 May 2025
- Timestamp
- 1:22:42 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available. The surrounding passage uses figurative ages (600, 550 years) in his theory of cancer as a 'defence plan'.
- Claimed mechanism
Tissue damage from disturbed digestion accelerates cancer as a 'defence plan'.
- Claimed health effect
Earlier cancer.
- Population concerned
Sleeve patients
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
That sleeve brings cancer forward.
2. What is demonstrably correct?
Long-term reflux and Barrett's after sleeve are documented (C-BAR-04), so a site-specific oesophageal risk is biologically plausible; in a French national cohort oesophageal cancer after sleeve was rare (about 4 per 100,000 person-years) and not significantly different from bypass (HR 1.60, 0.90-2.5; I-BAR-117). Nordic registry data show higher cancer mortality 15+ years after (mostly older) procedures (I-BAR-104).
3. What is wrong or exaggerated?
Overall cancer incidence and cancer mortality were lower, not higher, after bariatric surgery: SOS cancer death HR 0.77 (A-BAR-05), Adams 60% lower cancer mortality (A-BAR-03), SOS 2007 cancer deaths 29 vs 47 (A-BAR-02), SPLENDID 10-year obesity-related cancer 2.9% vs 4.9% (I-BAR-118), upper GI cancer RR 0.58 and oesophageal cancer RR 0.63 (I-BAR-119). Nothing supports cancer appearing "decades earlier".
4. What remains unclear?
Sleeve-specific long-term cancer data are limited.
5. Which studies support it?
None directly. Limiting: I-BAR-104 (late cancer mortality HR 1.20, older procedures); I-BAR-117 (oesophageal cancer after sleeve vs bypass HR 1.60, not significant).
6. Which studies contradict it?
A-BAR-02, A-BAR-03, A-BAR-05, I-BAR-118, I-BAR-119, I-BAR-102.
7. What applies to Germany and Europe?
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. What is known about Egypt?
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. What practical conclusion is appropriate?
There is no evidence that sleeve generally causes earlier cancer; cancer risk overall is lower after surgery. Reflux-related oesophageal risk should be monitored, and normal cancer screening continues after surgery.
Assessment details
- Rationale for certainty of evidence
Several large matched cohorts and meta-analyses consistently show lower cancer incidence and cancer mortality after bariatric surgery, including cohorts with many sleeve operations (SPLENDID I-BAR-118: obesity-related cancer aHR 0.68, cancer death aHR 0.52; I-BAR-102: sleeve cancer death HR 0.26 at 3 years) and specifically for oesophageal cancer (meta-analysis RR 0.63, I-BAR-119). Evidence is observational; a late cancer-mortality signal in Nordic registry data (HR 1.20 at >=15 years, mostly older procedures, I-BAR-104) and the long-term oesophageal risk after sleeve remain unresolved, hence not “False”/high.
- Source quality
Theory-based statement; no data cited.
- Regional transferability
Applicable.
- Individual exceptions
Possible procedure-specific risks (e.g., oesophageal adenocarcinoma after long-term reflux) are not yet quantified.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: Does sleeve gastrectomy (or bariatric surgery) make cancer appear earlier or more often than in comparable people with obesity?
Research question in detail (PICO)
- Population
- Adults with obesity
- Intervention or exposure
- Sleeve gastrectomy; bariatric surgery
- Comparison
- Matched non-operated people with obesity; gastric bypass
- Geographic scope
- universal biology
- Outcomes
- Cancer incidence (obesity-related, upper GI, oesophageal)
- Cancer mortality
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Nordic study: survival after obesity surgery
Kauppila et al.. Gastroenterology 2019 · PMID 30940524 · DOI 10.1053/j.gastro.2019.03.048 Cohort studyabstract checkednewly addedNordic registry: cancer mortality lower overall but higher at >=15 years after surgery (mostly older procedures).
- Actual result
- HR 0.84 overall; 1.20 (1.02-1.42) at >=15 y.
- Methodological quality
- moderate
- Relevance
- indirect (few sleeves)
- Limitations
- Registry confounding
French national study: oesophageal cancer after sleeve vs bypass
Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002 Cohort studyabstract checkednewly addedFrench national cohort: oesophageal cancer after sleeve vs bypass not significantly different, point estimate higher.
- Actual result
- HR 1.60 (0.90-2.5); 3.9/100,000 PY after SG.
- Methodological quality
- moderate
- Relevance
- direct for oesophageal cancer
- Limitations
- Rare outcome
What speaks against the claim?
US study: cancer after weight-loss surgery
Aminian et al.. JAMA 2022 · PMID 35657620 · DOI 10.1001/jama.2022.9009 Cohort studyfull text checkednewly addedSPLENDID: fewer obesity-related cancers and cancer deaths after surgery (one third sleeve).
- Actual result
- aHR 0.68 (0.53-0.87); cancer death aHR 0.52 (0.31-0.88); 10-y 2.9% vs 4.9%.
- Methodological quality
- moderate
- Relevance
- direct
- Limitations
- Single system
Meta-analysis: upper digestive cancers after weight-loss surgery
Cooke et al.. BJS Open 2025 · PMID 41947341 · DOI 10.1093/bjsopen/zrag006 Meta-analysisabstract checkednewly addedMeta-analysis: upper GI cancers, including oesophageal, less frequent after surgery.
- Actual result
- RR 0.58; oesophageal RR 0.63 (0.40-0.98).
- Methodological quality
- moderate
- Relevance
- direct
- Limitations
- Procedures mixed
Swedish 24-year study: surgery added about 3 years of life
Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449 Cohort studyfull text checkedSOS 24 years: cancer deaths lower after surgery.
- Actual result
- HR 0.77 (0.61-0.96).
- Methodological quality
- moderate-high
- Relevance
- indirect (no sleeve)
- Limitations
- Non-randomised
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Cancer incidence and cancer mortality are lower, not higher, after bariatric surgery including cohorts with many sleeve operations; a possible small long-term oesophageal risk after sleeve is not excluded.
Why some studies weigh more
Several large matched cohorts and meta-analyses with consistent direction; sleeve-specific data (I-BAR-102 cancer death HR 0.26 at 3 y) included.
Is a causal relationship established? Probable Consistent reduction with weight loss; observational.
Remaining uncertainty
Oesophageal adenocarcinoma after decades of sleeve-related reflux; late cancer-mortality signal in Nordic data.
Justified conclusion
The claim that sleeve brings cancer decades forward is not supported and is contradicted for cancer overall.
Why do studies seem to disagree?
The late Nordic signal (HR 1.20 at >=15 y) concerns mostly older procedures and may reflect confounding; it does not match the claim of cancer decades earlier, and other cohorts show reductions.
Does this depend on the country?
- General biological effects
- Universal.
- Eating habits
- Not applicable (surgical procedure, not a food).
- Origin of the food
- Not applicable (surgical procedure, not a food).
- Contaminants
- Not applicable (surgical procedure, not a food).
- National production conditions
- Not applicable.
- Legal rules
- Not applicable.
- Actual monitoring data
- No Egyptian data found.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Absolute risk reduction and NNT; CI symmetry – 10-y ARR 2.0% (NNT ~50) for obesity-related cancer; 0.6% (NNT ~167) for cancer death; CIs symmetric. recalculated
- Late cancer mortality HR CI – HR 1.20 (1.02-1.42) symmetric; lower bound close to 1. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Cancer incidence/mortality after bariatric surgery vs obese controls
- Starting level
- low (observational studies)
- Reasons for upgrading
- consistency across large cohorts and meta-analyses
- dose-response with weight loss (SPLENDID)
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | (TITLE:"cancer") AND (TITLE:"bariatric surgery" OR TITLE:"sleeve gastrectomy" OR TITLE:"metabolic surgery") AND (TITLE:"incidence" OR TITLE:"risk") AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis" OR TITLE:"cohort") AND PUB_YEAR:[2019 TO 2026] | both directions | 35 | |
| PubMed | 26 October 2026 | Aminian A[au] AND bariatric surgery AND obesity-associated cancer AND mortality AND JAMA[ta] | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | (TITLE:"esophageal adenocarcinoma" OR TITLE:"oesophageal adenocarcinoma" OR TITLE:"esophageal cancer" OR TITLE:"oesophageal cancer" OR TITLE:"esophagogastric cancer") AND (TITLE:"sleeve gastrectomy" OR TITLE:"bariatric" OR TITLE:"obesity surgery") | both directions | 33 |
Open questions
Oesophageal adenocarcinoma incidence >20 years after sleeve.
How deeply was this checked?
10 linked studies: 3 checked in full text (0 of them with a structured risk-of-bias assessment), 7 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (low)
- 26 October 2026 · Phase 4 (systematic evidence review) · Verdict changed: Mostly false (low) → Mostly false (moderate)
Verdict “Mostly false” kept; certainty raised from low to moderate because new large matched cohorts (I-BAR-118, I-BAR-102) and a 2025 meta-analysis (I-BAR-119) consistently show lower cancer incidence/mortality after surgery, including cohorts with many sleeve operations and specifically oesophageal cancer. “Mostly false” rather than “False” because the long-term oesophageal risk after sleeve and a late Nordic cancer-mortality signal remain unresolved.
New sources: I-BAR-102 I-BAR-115 I-BAR-118 I-BAR-119 I-BAR-104 I-BAR-117
In plain language
Elawady claimed that sleeve gastrectomy makes cancer appear much earlier. Large studies found the opposite for cancer overall: fewer cancers and fewer cancer deaths after weight-loss surgery than in similar people without surgery, including in studies where many patients had a sleeve. Cancer of the gullet after sleeve is rare. Whether long-term reflux after sleeve slightly raises the risk of this cancer is still unknown.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (7)
-
Swedish study: fewer deaths after weight-loss surgery
Sjöström L et al.. N Engl J Med 2007 · PMID 17715408 · DOI 10.1056/NEJMoa066254Cohort studycited by the Tayebat archiveabstract checkedOver about 11 years, people who had surgery had roughly 24-29% lower risk of dying than matched controls.
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test mortality effect
- How was the study done?
Prospective matched study
- How many people, animals or samples were studied?
4047 adults
- What was actually found?
Fewer deaths after surgery
- How large was the observed effect?
Adjusted HR 0.71
- What do the results mean in everyday life?
Surgery was linked to living longer
- What are the study's limitations?
Not randomized; older techniques
- What does it say about Elawady's specific claim?
Argues against 'surgery kills'
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Exact causal size
-
Gastric bypass: fewer deaths overall, but more accident and suicide deaths
Adams TD et al.. N Engl J Med 2007 · PMID 17715409 · DOI 10.1056/NEJMoa066603Cohort studycited by the Tayebat archiveabstract checked★ key studyTotal deaths were 40% lower after surgery, while deaths from accidents and suicide were higher (11.1 vs 6.4 per 10,000 person-years).
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Long-term mortality
- How was the study done?
Matched retrospective cohort
- How many people, animals or samples were studied?
15,850 people
- What was actually found?
Total deaths down, external-cause deaths up
- How large was the observed effect?
37.6 vs 57.1 total; 11.1 vs 6.4 non-disease per 10,000 PY
- What do the results mean in everyday life?
Net survival benefit with a specific mental health and accident risk
- What are the study's limitations?
Observational
- What does it say about Elawady's specific claim?
Supports self-harm concern, contradicts 'lethal'
- Do the results apply to Germany and Europe?
Comparable to Nordic findings
- What can explicitly not be concluded from this study?
Causation of suicide excess
-
Swedish 24-year study: surgery added about 3 years of life
Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449Cohort studycited by the Tayebat archivefull text checked★ key studyOperated patients lived about 3 years longer than non-operated patients with obesity, but still about 5.5 years less than the general population (non-operated: about 8.5 years less).
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Life expectancy
- How was the study done?
Prospective controlled cohort with population reference
- How many people, animals or samples were studied?
5182 people
- What was actually found?
Surgery gained 3 years; gap to population 5.5 vs 8.5 years
- How large was the observed effect?
HR death 0.77; +3.0 years
- What do the results mean in everyday life?
Surgery reduced but did not remove the life-expectancy loss linked to severe obesity
- What are the study's limitations?
Not randomized; old operations
- What does it say about Elawady's specific claim?
Number correct, implication 'surgery shortens life' wrong
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
That surgery causes the remaining 5.5-year gap
-
US study: survival after sleeve and bypass
Courcoulas et al.. Ann Surg 2023 · PMID 34387200 · DOI 10.1097/SLA.0000000000005155Cohort studyindependent cross-checkfull text checked★ key studyOver 5 years, people who had a sleeve died about 70% less often than similar people who did not have surgery (1.0% vs 2.7%).
Lower cancer-related mortality at 3 y after SG.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare deaths after SG/RYGB with matched non-operated patients
- How was the study done?
Matched cohort, health records
- How many people, animals or samples were studied?
13,900 SG; 17,258 RYGB; 87,965 controls
- What was actually found?
Lower death rates after both operations
- How large was the observed effect?
SG HR 0.28 (0.13-0.57)
- What do the results mean in everyday life?
Sleeve was not associated with earlier death
- What are the study's limitations?
About one third lost to follow-up; observational
- What does it say about Elawady's specific claim?
Contradicts "sleeve kills"
- Do the results apply to Germany and Europe?
Plausible for Europe and Egypt
- What can explicitly not be concluded from this study?
Cannot exclude unmeasured confounding
-
Sleeve vs a weight-loss drug: Barrett changes
Butt et al.. Ann Gastroenterol 2026 · PMID 42164611 · DOI 10.20524/aog.2026.1058Cohort studyindependent cross-checkabstract checkedBarrett changes were diagnosed in 0.3% after sleeve vs 0.1% with liraglutide; cancer did not differ.
No difference in oesophageal cancer.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare BE after SG vs liraglutide
- How was the study done?
Matched EHR cohort
- How many people, animals or samples were studied?
20,096
- What was actually found?
BE 0.3% vs 0.1%
- How large was the observed effect?
RR 2.70
- What do the results mean in everyday life?
Small absolute increase
- What are the study's limitations?
Detection bias
- What does it say about Elawady's specific claim?
Supports a modest relative increase
- Do the results apply to Germany and Europe?
US data
- What can explicitly not be concluded from this study?
Cancer risk
-
US study: cancer after weight-loss surgery
Aminian et al.. JAMA 2022 · PMID 35657620 · DOI 10.1001/jama.2022.9009Cohort studyindependent cross-checkfull text checked★ key studyOver 10 years, obesity-related cancer occurred in 2.9% after surgery vs 4.9% without; cancer deaths 0.8% vs 1.4%.
Lower obesity-associated cancer (aHR 0.68) and cancer mortality (aHR 0.52).
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Cancer risk after surgery
- How was the study done?
Matched cohort
- How many people, animals or samples were studied?
30,318
- What was actually found?
Fewer cancers and cancer deaths
- How large was the observed effect?
aHR 0.68 and 0.52
- What do the results mean in everyday life?
Surgery was linked to less cancer, not more
- What are the study's limitations?
Observational, single system
- What does it say about Elawady's specific claim?
Contradicts the claim
- Do the results apply to Germany and Europe?
Plausible
- What can explicitly not be concluded from this study?
Sleeve-only long-term effect
-
Meta-analysis: upper digestive cancers after weight-loss surgery
Cooke et al.. BJS Open 2025 · PMID 41947341 · DOI 10.1093/bjsopen/zrag006Meta-analysisindependent cross-checkabstract checked★ key studyPeople who had surgery had about 40% fewer upper digestive cancers, including cancer of the gullet.
Upper GI cancer RR 0.58; oesophageal RR 0.63.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Upper GI cancer after surgery
- How was the study done?
Meta-analysis
- How many people, animals or samples were studied?
>5.7 million
- What was actually found?
Lower risk
- How large was the observed effect?
RR 0.58
- What do the results mean in everyday life?
No sign of earlier cancer
- What are the study's limitations?
Observational, mixed procedures
- What does it say about Elawady's specific claim?
Contradicts the claim
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Sleeve-only data
No study in this group is marked as key.
Studies with mixed or unclear results (3)
-
Meta-analysis: Barrett's after sleeve
Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041Meta-analysisindependent cross-checkabstract checked★ key studyAbout 5.6% developed new Barrett's esophagus; reflux and acid-medication use were about 3 times more frequent after sleeve.
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
BE after SG
- How was the study done?
Meta-analysis
- How many people, animals or samples were studied?
2046
- What was actually found?
BE 5.6%; GERD x3
- How large was the observed effect?
RR GERD 3.32
- What do the results mean in everyday life?
Reflux is a major downside of sleeve
- What are the study's limitations?
Heterogeneous observational
- What does it say about Elawady's specific claim?
Supports reflux/BE claim, not 'inevitable'
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Cancer risk
-
Nordic study: survival after obesity surgery
Kauppila et al.. Gastroenterology 2019 · PMID 30940524 · DOI 10.1053/j.gastro.2019.03.048Cohort studyindependent cross-checkabstract checked★ key studyOperated people died less often than non-operated people with obesity, but more often than the general population; suicide deaths were more frequent.
Cancer mortality lower overall but HR 1.20 at >=15 y (mostly older procedures).
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare survival with two reference groups
- How was the study done?
Registry cohort
- How many people, animals or samples were studied?
505,258 (49,977 operated)
- What was actually found?
HR 0.63 vs obese; SMR 1.94 vs general population
- How large was the observed effect?
All-cause HR 0.63; suicide HR 1.68
- What do the results mean in everyday life?
Surgery reduces but does not remove the excess risk of obesity
- What are the study's limitations?
Older procedures; registry data
- What does it say about Elawady's specific claim?
Contradicts "lethal", supports "still shorter life than general population"
- Do the results apply to Germany and Europe?
Direct European data
- What can explicitly not be concluded from this study?
Sleeve-specific long-term effects
-
French national study: oesophageal cancer after sleeve vs bypass
Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002Cohort studyindependent cross-checkabstract checked★ key studyOesophageal cancer was rare after both operations (about 4 per 100,000 per year after sleeve) and not significantly different.
Oesophageal cancer ~3.9/100,000 PY after SG; HR vs GB 1.60 (0.90-2.5).
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare cancer risk SG vs GB
- How was the study done?
National cohort
- How many people, animals or samples were studied?
370,271
- What was actually found?
No significant difference
- How large was the observed effect?
HR 1.60 (0.90-2.5)
- What do the results mean in everyday life?
Cancer of the gullet after sleeve is rare
- What are the study's limitations?
Coding; borderline result
- What does it say about Elawady's specific claim?
Contradicts "cancer comes decades earlier"; leaves small uncertainty
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Risk vs no surgery
No study in this group is marked as key.
Regional context
Germany / EU
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
Egypt
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
What applies in my country?
General scientific assessment
Mostly false False as stated: fewer cancers and cancer deaths occur after bariatric surgery, including sleeve; only a possible small long-term oesophageal risk remains unresolved.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Effects of bariatric surgery on mortality in Swedish obese subjects.. Sjöström L et al.. N Engl J Med 2007 · PMID 17715408 · DOI 10.1056/NEJMoa066254
- Long-term mortality after gastric bypass surgery.. Adams TD et al.. N Engl J Med 2007 · PMID 17715409 · DOI 10.1056/NEJMoa066603
- Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study.. Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449
- Reduction in Long-term Mortality After Sleeve Gastrectomy and Gastric Bypass Compared to Nonsurgical Patients With Severe Obesity.. Courcoulas et al.. Ann Surg 2023 · PMID 34387200 · DOI 10.1097/SLA.0000000000005155
- Incidence of Barrett's esophagus and esophageal cancer following sleeve gastrectomy versus liraglutide therapy.. Butt et al.. Ann Gastroenterol 2026 · PMID 42164611 · DOI 10.20524/aog.2026.1058
- Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity.. Aminian et al.. JAMA 2022 · PMID 35657620 · DOI 10.1001/jama.2022.9009
- Upper gastrointestinal cancer risk following bariatric surgery: meta-analysis.. Cooke et al.. BJS Open 2025 · PMID 41947341 · DOI 10.1093/bjsopen/zrag006
- Risk of De Novo Barrett's Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up.. Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041
- Effects of Obesity Surgery on Overall and Disease-Specific Mortality in a 5-Country Population-Based Study.. Kauppila et al.. Gastroenterology 2019 · PMID 30940524 · DOI 10.1053/j.gastro.2019.03.048
- Risk assessment for esophageal cancer after bariatric surgery: a comparative cohort study between sleeve gastrectomy and gastric bypass.. Lazzati et al.. Surg Obes Relat Dis 2025 · PMID 39799019 · DOI 10.1016/j.soard.2024.12.002